Allogene Therapeutics
Marcel Meury, PhD, is a Senior Scientist at Allogene Therapeutics and a Scientist II at Five Prime Therapeutics, Inc., with extensive experience in protein chemistry, immuno-oncology, and antibody engineering. Contributions include improving the stability and solubility of GPCR antigens for pre-clinical studies and leading protein design projects. Previously, Marcel held postdoctoral positions at the University of Basel and Paul Scherrer Institut, focusing on synthetic biotin pathways and serotonin receptor engineering. Education includes a PhD in Biochemistry from the University of Bern, and both a Master's and Bachelor's degree in Structural and Molecular Biology from the University of Basel. Early career experience includes work as a Medical Laboratory Assistant at University Hospital Basel.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.